David Hollander

Directeur de la R&D

Aerie Pharmaceuticals IncRevance Therapeutics, Inc.Veradermics, Inc

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 1 saleDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€15k

Latest filing published 03 Sept 2026 for Veradermics, Inc. Read the official filing

Filing timeline

BuySale

David Hollander

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

David Hollander: trading record in brief

David Hollander (senior executive) discloses dealings in 3 companies, chiefly Aerie Pharmaceuticals Inc, Revance Therapeutics, Inc. and Veradermics, Inc. The record holds 5 filings, for trades running from 11 November 2021 to 1 September 2026.

The open-market record consists of 1 sale worth €15k, with no purchase. Outside the open market, there are 3 share grants.

Most recently, on 3 September 2026, the filings show a share grant in Veradermics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.